MedTrace Logo

WHENII - Early Response Evaluation With FDG-PET/CT and Liquid Biopsy in Patients With NSCLC

NCT03481101 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-10-08

No results posted yet for this study

Summary

Response evaluation with FDG-PET and free circulating DNA in patients with inoperable lung cancer of non small cell type during first treatment with chemotherapy or immunotherapy.

Conditions

  • Non Small Cell Lung Cancer
  • Circulating Tumor Cell
  • Circulating Tumor DNA

Interventions

DEVICE

PET/CT

3 extra scans with FDG-PET/CT and 4 blood samples

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Andreas Kjær · Klinisk fysiologisk og Nuclearmedicinsk afd

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-28
Primary Completion
2021-02-26
Completion
2021-02-28

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03481101 on ClinicalTrials.gov